News | June 11, 2009

RF Thermal Ablation Device Outperforms Endovenous Laser


June 11, 2009 - According to a study published by the Journal of Vascular & Interventional Radiology, the VNUS ClosureFAST system for radiofrequency (RF) thermal ablation is "significantly superior" to endovenous laser (EVL) for treating venous reflux, the underlying cause of symptomatic varicose veins.   The VNUS ClosureFAST catheter is a minimally invasive device generally used in the physician's office with a local anesthetic to heat and seal the great saphenous vein, the most common site of venous reflux in the leg. The RECOVERY trial was a multicenter, randomized, single-blinded study of 87 vein ablation procedures in 69 patients, comparing the ClosureFAST radiofrequency catheter to the 980 nm endovenous laser system. The study found that for all primary endpoints in the trial, the ClosureFAST radiofrequency catheter was statistically superior to laser treatment in providing a fast and comfortable recovery for the patient after treatment. Specifically, radiofrequency vein ablation using the ClosureFAST catheter was shown to result in less postoperative pain, less bruising, less tenderness, and better reduction of symptoms than laser as soon as two days after treatment, and remaining considerably better for at least two weeks or longer. In addition, all statistical differences in postprocedural and quality-of-life parameters were superior in the ClosureFAST group, and minor complications were five times less prevalent.   "The study found RF thermal ablation, as performed with the ClosureFAST catheter, superior to EVL as measured by a comprehensive array of postprocedural recovery and QOL comparisons between these two minimally invasive techniques for closure of the greater saphenous vein," said Jose I. Almeida, M.D., lead author of the study and Medical Director of Miami Vein Center.   "The study confirms what many of us who have used both laser and radiofrequency devices have felt subjectively - that there is significantly enhanced patient comfort with the radiofrequency technology," said Raymond G. Makhoul, M.D., of Richmond, Virginia, a researcher for the study. "The ClosureFAST device clearly provided a superior patient experience." For more information: www.vnus.com


Related Content

News | Venous Therapies

October 14, 2022 — Medtronic, a global leader in medical technology, announced the 36-month final results from the ABRE ...

Home October 14, 2022
Home
News | Venous Therapies

November 22, 2021 — Fewer than 10 days of low-molecular-weight heparin (LMWH) after stenting for extensive iliofemoral ...

Home November 22, 2021
Home
News | Venous Therapies

February 22, 2021 — The U.S. Food and Drug Administration (FDA) recently cleared the Cook Medical Zilver Vena Venous ...

Home February 22, 2021
Home
News | Venous Therapies

October 26, 2020 — The U.S. Food and Drug Administration (FDA) has cleared the Medtronic Abre venous self-expanding ...

Home October 26, 2020
Home
News | Venous Therapies

October 31, 2019 – In a large series of iliac vein stent cases, a blinded comparison found intravascular ultrasound ...

Home October 31, 2019
Home
Technology | Venous Therapies

May 6, 2019 — The U.S Food and Drug Administration (FDA) has cleared the Boston Scientific Vici Venous Stent System for ...

Home May 06, 2019
Home
Technology | Venous Therapies

April 3, 2019 — The U.S. Food and Drug Administration (FDA) recently cleared Bard Peripheral Vascular's Venovo Venous ...

Home April 03, 2019
Home
News | Venous Therapies

August 8, 2018 — Boston Scientific Corp. announced it has signed an agreement to acquire Veniti Inc., which has ...

Home August 08, 2018
Home
Feature | Venous Therapies | Tif Siragusa, M.D.

The introduction of thermal ablation revolutionized the treatment of varicose veins, yet recurrence remains a stubborn ...

Home April 30, 2018
Home
News | Venous Therapies

January 26, 2018 – Medtronic plc announced the initiation of its investigational device exemption (IDE) study for the ...

Home January 26, 2018
Home
Subscribe Now